The skyrocketing demand for telemedicine and expansion of reimbursement for telehealth visits due to COVID-19 is likely going to shift the paradigm for diabetes care delivery into the future, setting up diabetes software company Glooko, Inc. for continued growth.
When the first shelter-in-place regulations kept diabetes patients from seeing their doctors in the office due to the pandemic, the...